CliffBio
biologic

Bkemv

eculizumab-aeeb

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameBkemv
Active ingredienteculizumab-aeeb
Strength300MG/30ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2024
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Bkemv patent cliff — loss of exclusivity — | CliffBio